Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Deferred Taxes (2019 - 2025)

Historic Deferred Taxes for Vanda Pharmaceuticals (VNDA) over the last 8 years, with Q4 2025 value amounting to $103.2 million.

  • Vanda Pharmaceuticals' Deferred Taxes rose 549111.81% to $103.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $81.4 million, marking a year-over-year increase of 135644.86%. This contributed to the annual value of $81.4 million for FY2025, which is 135644.86% up from last year.
  • Vanda Pharmaceuticals' Deferred Taxes amounted to $103.2 million in Q4 2025, which was up 549111.81% from -$6.0 million recorded in Q3 2025.
  • Vanda Pharmaceuticals' Deferred Taxes' 5-year high stood at $103.2 million during Q4 2025, with a 5-year trough of -$8.0 million in Q2 2025.
  • For the 5-year period, Vanda Pharmaceuticals' Deferred Taxes averaged around $4.1 million, with its median value being $85500.0 (2022).
  • Data for Vanda Pharmaceuticals' Deferred Taxes shows a peak YoY increase of 549111.81% (in 2025) and a maximum YoY decrease of 306951.22% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Deferred Taxes stood at $1.3 million in 2021, then tumbled by 68.24% to $417000.0 in 2022, then crashed by 1894.72% to -$7.5 million in 2023, then soared by 74.43% to -$1.9 million in 2024, then surged by 5491.12% to $103.2 million in 2025.
  • Its Deferred Taxes stands at $103.2 million for Q4 2025, versus -$6.0 million for Q3 2025 and -$8.0 million for Q2 2025.